Menlo Therapeutics Inc. (MNLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNLO Stock Summary
- With a year-over-year growth in debt of 3,390.94%, Menlo Therapeutics Inc's debt growth rate surpasses 99.06% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Menlo Therapeutics Inc is reporting a growth rate of 255.12%; that's higher than 94.8% of US stocks.
- As for revenue growth, note that MNLO's revenue has grown 667.89% over the past 12 months; that beats the revenue growth of 98.83% of US companies in our set.
- Stocks that are quantitatively similar to MNLO, based on their financial statements, market capitalization, and price volatility, are TRXC, COHR, RENN, FSLR, and CMRX.
- MNLO's SEC filings can be seen here. And to visit Menlo Therapeutics Inc's official web site, go to www.menlotherapeutics.com.
MNLO Stock Price Chart Interactive Chart >
MNLO Price/Volume Stats
| Current price | $1.35 | 52-week high | $7.48 |
| Prev. close | $1.38 | 52-week low | $1.00 |
| Day low | $1.30 | Volume | 1,561,200 |
| Day high | $1.39 | Avg. volume | 2,817,431 |
| 50-day MA | $1.63 | Dividend yield | N/A |
| 200-day MA | $2.95 | Market Cap | 226.38M |
Menlo Therapeutics Inc. (MNLO) Company Bio
Menlo Therapeutics Inc., a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials in pruritus associated with psoriasis and atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is based in Redwood City, California.
Latest MNLO News From Around the Web
Below are the latest news stories about Menlo Therapeutics Inc that investors may wish to consider to help them evaluate MNLO as an investment opportunity.
What You Need To Know About Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Investor CompositionA look at the shareholders of Menlo Therapeutics Inc. (NASDAQ:MNLO) can tell us which group is most powerful... |
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in SeptemberBRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment Conference Date:September 14 Time:2:30pm Eastern Time Webcast:https://wsw.com/webcast/hcw7/vyne/1630674 Cantor Fitzgerald Virtual Global Healthcare Conference Date:September 16 Time:10:00am Eastern Time Webcast:https://www.webcaster4.com/Webcast/Page/2495/37311 The Cantor Fitzgerald presentation will take the form of a “Fireside Chat” with analyst Louise Chen.About VYNE Therapeutics Inc. VYNE Thera... |
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE TherapeuticsVYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE". The name and ticker symbol changes are effective as of the opening of trading today, September 8, 2020. |
Menlo Therapeutics Announces Corporate Name Change to VYNE TherapeuticsCompany will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc. (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “VYNE”. The name and ticker change will be effective at the opening of trading, Tuesday, September 8, 2020. In addition, VYNE Therapeutics will ring the Nasdaq closing bell on September 8, at 4:00 PM ET. “Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our ... |
Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call TranscriptMenlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Sadia Rahman... |
MNLO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -35.10% |
| 3-year | -83.35% |
| 5-year | N/A |
| YTD | N/A |
| 2020 | 0.00% |
| 2019 | 12.62% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...